Dr. Brad McGregor

And so it really established a new standard of care.

Now, at the same time, there's a ton of questions that we now answer ourselves.

It's like, do we really need to have pre- and post-op therapy?

A third of patients did not get adjuvant therapy.

Why did they not get adjuvant therapy?

What happened to those patients?

What's that breakdown?

I think those are going to be key questions.

As we look to the future, all we know is past CR versus no past CR.

What were those no past CR breakdowns?

Were those some TA, T1, CAS?

What actually was being seen there?

What about CTA?

We see a really nice analysis from Agra.

Are we going to see the same thing here?

So a lot of unanswered questions.

But at the same time, I think it really does tell us that we now have a highly effective systemic therapy

offer in the perioperative setting to patients who are in that cisplatin-based therapy.

And the only way we're going to offer that patient is if we see those patients.

And so I think it's just critical that medical oncology be involved with all patients with muscle-based hepatic cancer early on in that treatment course.